May 19, 2022

The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) today jointly released recommendations that address the lack of equity, diversity, and inclusion (EDI) in cancer clinical trials. Published in the Journal of Clinical Oncology, “Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement” details specific actions to engage the entire cancer clinical trial ecosystem in expanding the participation of underrepresented individuals in research that advances progress against cancer.

May 3, 2022

Oncology professionals from around the world will convene in Chicago to discuss the latest clinical cancer research impacting patient care at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Advances in therapies for rare and pediatric cancers, findings on disparities among patients with cancer, and new treatment options for patients with advanced breast, colorectal, and pancreatic cancers are among the topics that will be highlighted in the meeting’s official Press Program.  

May 3, 2022

Alexandria, Va. – Today the American Society of Clinical Oncology (ASCO) announced six additional medical schools will participate in the second year of the Oncology Summer Internship (OSI) program, an immersive, four-week summer internship for rising second-year medical students from groups underrepresented in medicine (UIM).1 In 2022, ASCO and a total of 11 medical schools will lead approximately 50 students in a hybrid curriculum developed by members of ASCO’s OSI Advisory Group and each participating medical school’s internship leaders.

May 3, 2022

ASCO's CancerLinQ and Atropos Health announced on May 3 a collaboration that will provide oncology clinicians with the latest real-world evidence available to help inform personalized care and treatment of an individual patient.

April 18, 2022

The addition of tislelizumab to chemotherapy showed statistical and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone in patients with recurrent/metastatic nasopharyngeal cancer. These findings will be presented during the ASCO Plenary Series session taking place April 19, 2022, at 3:00 p.m. ET. 

April 12, 2022

The American Society of Clinical Oncology (ASCO) today announced the establishment of the ASCO Center for Equity, Diversity, and Inclusion, which will advance the Society’s equity, diversity, and inclusion (EDI) goals across the organization and throughout the wider oncology community. ASCO Chief Equity, Diversity and Inclusion Officer Sybil Green will serve as the Center’s inaugural vice president with lead responsibility for guiding and organizing the organization’s far-reaching external and internal EDI efforts.
 

April 7, 2022

The Association for Clinical Oncology (ASCO) today presented Representatives Diana DeGette (D-CO-1) and Fred Upton (R-MI-6) with the annual Congressional Champion for Cancer Care Award in recognition of their commitment to legislation that focuses on medical innovation. The award honors Members of Congress who are leading champions for patients and survivors of cancer, their families, and their care delivery teams.

April 7, 2022

The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Edward Balaban, DO, FACP, FASCO for his valuable contributions to ASCO’s advocacy efforts. The award recognizes volunteers who have gone above and beyond in the past year, advocating on behalf of patients and providers to improve cancer care and research.

April 5, 2022

Boston and Alexandria, VA – ASCO’s CancerLinQ® and Count Me In announced today a new collaboration that aims to allow cancer researchers to learn from every patient with cancer, by actively engaging patients as part of the clinical research enterprise. CancerLinQ – a real world oncology data technology platform developed by the American Society of Clinical Oncology (ASCO) – collects and aggregates de-identified EHR data from oncology practices across the United States to advance cancer care through quality improvement and research. Count Me In, a non-profit research initiative of the Broad Institute of MIT and Harvard, the Emerson Collective, and Dana-Farber Cancer Institute, provides patients with a mechanism to participate in cancer research by sharing their unique, de-identified medical information and history with cancer researchers and investigators.

April 4, 2022

The Association for Clinical Oncology (ASCO) congratulates Dr. Norman E. “Ned” Sharpless on his successful tenure as Director of the National Cancer Institute (NCI). During his five years at NCI, Dr. Sharpless guided the Institute to advance the goals of the Cancer Moonshot Initiative, including important work to modernize cancer clinical trials to reflect an improved understanding of biology and the new types of therapies available to treat cancer. We are hopeful that these efforts will endure even after Dr. Sharpless’ departure later this month.

March 29, 2022

While the Association for Clinical Oncology (ASCO) strongly believes in the stated mission of ARPA-H and its potential to innovate and expedite research, we are concerned that the Administration’s FY 2023 budget request invests in ARPA-H at the expense of the National Institutes of Health (NIH) and the National Cancer Institute (NCI)

March 14, 2022

Patients with advanced non-small cell lung cancer without EGFR/ALK mutations who were treated with toripalimab plus first-line chemotherapy had better progression-free survival and overall survival compared to patients who received chemotherapy alone, according to research from the CHOICE-01 trial. 

March 14, 2022

In patients with previously untreated metastatic or unresectable melanoma, the combination of nivolumab and relatlimab continued to demonstrate a progression-free survival benefit compared to nivolumab alone. The combination also demonstrated for the first time a higher overall response rate according to follow-up data from the RELATIVITY-047 trial. These data will be presented during an ASCO Plenary Series session taking place March 15, 2022, at 5:00 p.m. ET.

February 22, 2022

ALEXANDRIA, Va. – Jeffrey Peppercorn, MD, MPH, has been appointed as the next Editor-in-Chief of JCO Oncology Practice (JCO OP), an American Society of Clinical Oncology (ASCO) journal. JCO OP publishes impactful information and insights to keep oncology practice current on changes and challenges inherent in delivering equitable, high-quality oncology care with an evolving value-based lens.

 

February 15, 2022

The Association for Clinical Oncology (ASCO) congratulates Robert M. Califf, MD, on his confirmation by the United States Senate to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA). 

Pages